New pill targets immune cells to fight lung scarring
Disease control
Completed
This study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The drug aims to reduce scarring by blocking certain immune cells (NKT1 cells). Participants took either the drug or a…
Phase: PHASE2 • Sponsor: GRI Bio Operations, Inc. • Aim: Disease control
Last updated May 17, 2026 11:53 UTC